Table 3 Factors associated with progression-free survival: univariate and multivariate Cox proportional hazards models
Clinicopathologic parameters | Univariate Analysis | Multivariate Analysis | ||||
|---|---|---|---|---|---|---|
HR | 95% CI | p | HR | 95% CI | p | |
Age (years) | ||||||
≥ 75 vs. 64–75 | 1.292 | 1.056–1.581 | 0.013 | 1.217 | 0.955–1.550 | 0.112 |
Gender | ||||||
Male vs. Female | 1.158 | 0.935–1. 435 | 0.178 | |||
Weight loss | ||||||
Yes vs. No | 0.960 | 0.784–1. 175 | 0.692 | |||
Chemotherapy | ||||||
No vs. Yes | 1.416 | 1.157–1. 732 | 0.001 | 1.328 | 1.041–1.694 | 0.022 |
RT dose (Gy) | ||||||
≤ 58.8 vs. > 58.8 | 1.200 | 1.921–1. 564 | 0.176 | |||
Tumor location | ||||||
Cervical/Upper vs. Middle/Lower | 0.867 | 0.691–1. 088 | 0.219 | |||
Tumor length (cm) | ||||||
> 5.8 vs. ≤ 5.8 | 1.377 | 1.124–1. 687 | 0.002 | 1.179 | 0.950–1.465 | 0.135 |
Tumor thickness (cm) | ||||||
> 1.2 vs. ≤ 1.2 | 1.830 | 1.472–2.276 | < 0.001 | 1.498 | 1.184–1.894 | 0.001 |
T stage | ||||||
T4 vs. T2/T3 | 1.109 | 0.906–1. 359 | 0.316 | |||
N stage | ||||||
N2/N3 vs. N0/N1 | 1.589 | 1.262–2.001 | < 0.001 | 1.418 | 1.107–1.817 | 0.006 |
TNM stage | ||||||
Stage III/Stage IV vs. Stage II | 1.485 | 1.161–1.900 | 0.002 | 1.286 | 0.981–1.687 | 0.069 |
Year of diagnosis | ||||||
2007–2017 vs. 2018–2020 | 1.345 | 1.033–1.752 | 0.028 | 1.293 | 0.986–1.695 | 0.063 |
PNI | ||||||
≤ 41.7 vs. > 41.7 | 1.682 | 1.290–2.193 | < 0.001 | 1.237 | 0.912–1.677 | 0.172 |
NLR | ||||||
> 4.44 vs. ≤ 4.44 | 1.659 | 1.221–2.255 | 0.001 | 1.216 | 0.839–1.762 | 0.301 |
PLR | ||||||
> 180 vs. ≤ 180 | 1.507 | 1.193–1.902 | 0.001 | 1.140 | 0.849–1.529 | 0.384 |
LMR | ||||||
≤ 3.73 vs. > 3.73 | 1.417 | 1.157–1.734 | 0.001 | 1.161 | 0.932–1.447 | 0.184 |
SII | ||||||
> 918 vs. ≤ 918 | 1.715 | 1.335–2.203 | < 0.001 | 1.246 | 0.890–1.744 | 0.200 |